CTLA4 and non-small cell lung carcinoma: As we all know, blocking immunosuppressive checkpoint inhibitors such as CTLA-4, programmed cell death protein-1 (PD-1) and related programmed death ligand 1 (PD-L1) has revolutionized the first-line treatment of advanced NSCLC.